For heart failure and New York Heart Association class II/III. ANDA 212572, held by Mylan Labs Ltd. Ferric Carboxymaltose.
As of Nov 16, 2026, ANDA 212572 (Ferric Carboxymaltose), held by Mylan Labs Ltd, was first approved by FDA on Jun 25, 2026, with 0 approved supplements and 0 published complete response letters.
Ferric carboxymaltose injection is indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 25, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ferric Carboxymaltose750MG IRON/15ML (50MG IRON/ML) · solution;intravenous | Ferric Carboxymaltose | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters